Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05810051 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exercise and Coronary Microvascular Disease

Study acronym: ExerciseCMD
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 20, 2026 (before its estimated April 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Apr 2026 to Apr 15, 2026
    • Study completion date: Oct 2027 to Oct 15, 2027
    • Site details revised
    v5
  2. Primary completion date: Apr 2025 to Apr 2026
    • Study completion date: Oct 2025 to Oct 2027
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2023 to Jul 31, 2023
    • Site details revised
    v3
  4. Primary endpoint revised
    • Secondary endpoints revised (6)
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exercise CMD is a prospective single-center, open-label, parallel arms randomized controlled trial. This trial aims to assess the impact of cardiac rehabilitation on top of optimal medical therapy on patient-reported outcomes in subjects with coronary microvascular disease and non-obstructive coronary artery disease. Patients will undergo a microvascular assessment using bolus thermodilution techniques and those with criteria for microvascular angina (IMR ≥ 25) will be invited to participate. Patients will be randomized in a 1:1 ratio to either optimal medical therapy (OMT) or OMT plus a program of cardiac rehabilitations (CR). After randomization, spiro-ergometry and a SAQ-19 will be performed in all patients. Medical therapy will be standardized in both arms and the CR group will follow 36 sessions of the personalized physical training program of cardiac rehabilitation. Approximately 204 subjects (102 in each group) will be included at one site (OLV Aalst, Belgium). Clinical Follow-Up will be planned at 4 months. Patients with CCTA performed in standard of care will be invited for control CCTA 6 +/- 1 month after the invasive procedure.
Trial Details
NCT Number NCT05810051
Lead Sponsor CoreAalst BV
Collaborators: Abbott Medical Devices
Conditions
(from sponsor)		 Coronary Microvascular Disease
Related terms Microvascular Angina
Enrollment 204 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov